\n<\/p>\n
KUALA LUMPUR, \u00a0\u00a0<\/span><\/p>\n Under the collaboration, EyRIS’ AI deep EyRIS is 42% owned by novaHEALTH Pte Ltd<\/b>, which in turn is Nova MSC’s General Manager, Mr According to En. Ahmad Fadhullah Fuzai, President of AMO<\/b>, “The deployment of SELENA+ is capable of detecting up to 3 Aside from that, Nova MSC’s Group Chief Executive He also pointed The push to In order to Melanoma is the Nova MSC signs MoU with AMO and RHAZES that will enable the deployment of its EyRIS’ AI-Deep Learning Technology, SELENA+ to more than 1,000 AMO members via RHAZES Telehealth service SELENA+ is capable of detecting up to 3 retinal diseases, principally diabetic retinopathy, glaucoma suspect and age-related macular degeneration EyRIS SELENA+ will also become a …<\/p>\n","protected":false},"author":1,"featured_media":20568,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[60],"tags":[],"_links":{"self":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/posts\/20567"}],"collection":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/comments?post=20567"}],"version-history":[{"count":0,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/posts\/20567\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/media\/20568"}],"wp:attachment":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/media?parent=20567"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/categories?post=20567"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/tags?post=20567"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nMALAYSIA –\u00a0Media OutReach<\/a>\u00a0– 21 February 2022 – Nova MSC
\nBerhad<\/b> (“Nova MSC” or
\n“the Company”), which is the exclusive distributor of EyRIS Pte Ltd’s (“EyRIS”)
\nproducts, has signed a Memorandum of Understanding (“MoU”) with the Association
\nof Malaysian Optometrists<\/b> (“AMO”) and Rhazes Consultancy Services Sdn
\nBhd<\/b> (“RHAZES”), a tele-pharmacy platform provider, to bring its AI Deep
\nLearning Technology, SELENA+<\/b> to mainstream adoption in Malaysia.\u00a0 <\/p>\n
\nlearning technology, SELENA+, will be deployed to AMO’s more than 1,000
\nmembers<\/b> across Malaysia via RHAZES Telehealth. RHAZES Telehealth is
\nMalaysia’s first knowledge-based telehealth service provider through its brand
\nRhazes TeleOpto. <\/p>\n
\nwholly-owned by Nova MSC.<\/p>\n
\nNazerollnizam Kasim<\/b>, said, “We are
\noptimistic that the collaboration with both AMO and RHAZES will drive forward
\nthe adoption of SELENA+ in Malaysia. During the pandemic, we have seen a rise
\nin telehealth and how it has gradually moved towards mainstream adoption.” <\/p>\n
\nSELENA+ to AMO’s member practices across the country will help to improve the
\nrange and quality of our services. This synergistic partnership with Nova will
\nsee the launch of SELENA+, and it will be deployed initially in 55 practices<\/b>
\nacross Malaysia through Rhazes’ TeleOpto Platform, eventually expanding to the
\nother member practices within a year.”<\/p>\n
\nretinal diseases<\/b>, principally diabetic retinopathy, glaucoma suspect and
\nage-related macular degeneration. Early screening and detection of these
\ndiseases can significantly reduce vision loss, and in the case of diabetic
\nretinopathy, studies have shown that diabetes-related vision loss can be
\nreduced by up to 47 percent. EyRIS’ SELENA+ has been approved for use by the
\nMalaysian Medical Device Authority since 22nd June 2020.\n<\/p>\n
\nthere will also be an addition of a new algorithm to detect chronic kidney disease
\n(“CKD”) through the same fundus image used by EyRIS’ SELENA+ to detect the 3
\nretinal diseases mentioned earlier. <\/p>\n
\nOfficer, Mr Lai Teik Kin<\/b> added, “The addition of this new
\nalgorithm will help us to be a gamechanger in the first stage diagnostic, a
\ndrive towards being able to implement rapid screening tools to aid early
\ndetection for systemic diseases. Our CKD algorithm boasts an 85 percent
\naccuracy rate, and uses of the non-invasive fundus imaging allows results to be
\ngenerated within 10-15 seconds<\/b> with ease, speed and accuracy,” Mr Lai
\nsaid. <\/p>\n
\nout that the recent gold award won by EyRIS at the Techblazer Awards 2021 in
\nthe Most Promising Innovation category is a sign of the Group’s push to bring
\nworld-class technology into the world. The Techblazer Awards is Singapore’s
\nhighest accolade<\/b> for technological innovation. <\/p>\n
\ndeploy SELENA+ into mainstream adoption in healthcare services has seen the
\navailability of its technology in 26 countries. <\/p>\n
\ncontinue to expand the capabilities in disease detection through its
\ncutting-edge AI deep learning technology, EyRIS has inked a Research
\nCollaboration Agreement with a specialty centre under the National Healthcare
\nGroup (NHG) to develop a new proprietary AI that detects melanoma using a
\nmobile phone camera. This was facilitated by NHG’s Centre for Medical
\nTechnologies and Innovations (CMTi). <\/p>\n
\ndeadliest form of skin cancer, and early detection is able to increase the
\n5-year survival rate to 99 percent. With 1 in every 3 cancer diagnoses being
\nskin cancer and the high melanoma incidence rate of 3.4 per 100,000 worldwide,
\nthe ability to detect skin cancer early through non-invasive, mobile imaging
\nwill contribute to the fight against skin cancer mortality. <\/p>\n<\/p><\/div>\n\n
Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"